Compare BBU & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBU | LGND |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | Bermuda | United States |
| Employees | N/A | 68 |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 2015 | N/A |
| Metric | BBU | LGND |
|---|---|---|
| Price | $31.46 | $223.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $39.40 | ★ $247.29 |
| AVG Volume (30 Days) | 48.7K | ★ 198.4K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.61 |
| Revenue Next Year | N/A | $18.93 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $98.90 |
| 52 Week High | $37.75 | $234.76 |
| Indicator | BBU | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 62.77 |
| Support Level | $29.90 | $180.85 |
| Resistance Level | $36.93 | $227.92 |
| Average True Range (ATR) | 1.38 | 8.69 |
| MACD | 0.23 | 2.50 |
| Stochastic Oscillator | 46.92 | 75.24 |
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.